

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

12 November 2025 | News

New facility strengthens High Potent API development and manufacturing for oncology products



Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin Limited, has announced the commissioning of its dedicated Oncology Block at its Vizag facility, Andhra Pradesh.

The new high-containment unit significantly enhances LMS's end-to-end Contract Development and Manufacturing capabilities for High Potent Active Pharmaceutical Ingredients. It will support clients across the oncology development lifecycle from preclinical research to commercial manufacturing, addressing growing global demand for oncology drug development and manufacturing.

Spanning 4,270 square meters, the new facility, is equipped with 20 reactors, ranging from 250L to 2000L, with over 20 isolators and advanced containment systems, ensuring exposure levels of $\leq 0.05 \mu\text{g}/\text{m}^3$. Designed with flexible scale-up capabilities (1–35 kg batch range) and comprehensive environmental controls ($\pm 25^\circ\text{C}$, $\pm 45\%$ RH), the facility allows for safe, efficient, and compliant production of oncology APIs that meet global quality standards.

The new facility integrates the Process Development Laboratory with a dedicated Quality Control laboratory, enabling early-stage route scouting, analytical development, process optimization, and validation—all in one location. Supported by scientists with specialized HPAPI expertise, it guarantees seamless transition from lab-scale synthesis to full-scale commercial manufacturing. The facility features advanced containment infrastructure, with isolator-based operations at every process step, integrated SCADA systems, and a robust effluent detoxification system that complies with global regulatory standards, while also adhering to Lupin's stringent quality and environmental safety protocols.

With this expansion, LMS strengthens its role as a trusted global CDMO partner for oncology innovators.